Keystone shows Gates the money

In our May issue, James Aiken, the CEO of the Keystone Symposia, linkurl:wrote that;http://www.the-scientist.com/article/display/23399/ ?the long reach of Bill Gates? had ?finally touched the Keystone Symposia, and all of conference planning, really.? Aiken was writing a grant proposal to the Foundation, and they required him to show measured value for the conferences. Aiken went on to describe a method for quantifying the conferences? impact. When he tallied the results of the instrument Keys

Written byIvan Oransky
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
In our May issue, James Aiken, the CEO of the Keystone Symposia, linkurl:wrote that;http://www.the-scientist.com/article/display/23399/ ?the long reach of Bill Gates? had ?finally touched the Keystone Symposia, and all of conference planning, really.? Aiken was writing a grant proposal to the Foundation, and they required him to show measured value for the conferences. Aiken went on to describe a method for quantifying the conferences? impact. When he tallied the results of the instrument Keystone used, the results were impressive: ?Conservative extrapolation to the entire Keystone Symposia season of meetings would suggest that at least $20 to $30 million in research funds is diverted to more effective use each year because of information learned at our conferences,? Aiken wrote. Those results seem to have impressed the Gates Foundation, too, which just linkurl:gave Keystone a $2.6 million grant;http://www.keystonesymposia.org/News/ to expand its Global Health Series. According to the Foundation, the survey results were one of the key factors in the foundation's decision to continue supporting Keystone. For tips on how to apply to non-profits for grants to support your own research, keep an eye out for our November issue.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies